Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Theodore Sunki Hong, M.D.

Co-Author

This page shows the publications co-authored by Theodore Hong and Lipika Goyal.
Connection Strength

3.680
  1. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021 Nov; 2(11):1124-1135.
    View in: PubMed
    Score: 0.243
  2. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.229
  3. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700.
    View in: PubMed
    Score: 0.224
  4. Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. Pract Radiat Oncol. 2020 May - Jun; 10(3):e183-e187.
    View in: PubMed
    Score: 0.213
  5. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.206
  6. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):64-72.
    View in: PubMed
    Score: 0.200
  7. Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol. 2018; 2:22.
    View in: PubMed
    Score: 0.196
  8. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 07 01; 4(7):963-969.
    View in: PubMed
    Score: 0.192
  9. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Med. 2018 May 17.
    View in: PubMed
    Score: 0.190
  10. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):414-421.
    View in: PubMed
    Score: 0.190
  11. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.181
  12. Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs). Ann Oncol. 2017 Jun; 28 Suppl 3:iii145-iii146.
    View in: PubMed
    Score: 0.178
  13. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.161
  14. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27.
    View in: PubMed
    Score: 0.157
  15. Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discov. 2022 Mar 23.
    View in: PubMed
    Score: 0.062
  16. Positron Emission Tomography/Magnetic Resonance Imaging Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis. Ann Surg. 2022 Feb 17.
    View in: PubMed
    Score: 0.062
  17. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. JCO Oncol Pract. 2021 12; 17(12):e1846-e1855.
    View in: PubMed
    Score: 0.059
  18. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 10 15; 27(20):5586-5594.
    View in: PubMed
    Score: 0.058
  19. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol. 2020 Dec; 27(13):5161-5172.
    View in: PubMed
    Score: 0.055
  20. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885.
    View in: PubMed
    Score: 0.053
  21. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020 Apr; 27(4):1122-1129.
    View in: PubMed
    Score: 0.053
  22. Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. Ann Oncol. 2019 Jul; 30 Suppl 4:iv112.
    View in: PubMed
    Score: 0.053
  23. PARP-ness in metastatic colorectal cancer. Ann Oncol. 2019 Jul; 30 Suppl 4:iv117.
    View in: PubMed
    Score: 0.053
  24. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Dec; 25(12):1949.
    View in: PubMed
    Score: 0.053
  25. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2020 07; 47(8):1871-1884.
    View in: PubMed
    Score: 0.053
  26. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 09; 25(9):1415-1421.
    View in: PubMed
    Score: 0.052
  27. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. Am J Clin Oncol. 2019 07; 42(7):564-572.
    View in: PubMed
    Score: 0.051
  28. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1222-1225.
    View in: PubMed
    Score: 0.047
  29. Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Ann Oncol. 2017 Jun; 28 Suppl 3:iii137.
    View in: PubMed
    Score: 0.045
  30. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15; 22(2):470-8.
    View in: PubMed
    Score: 0.040
  31. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7.
    View in: PubMed
    Score: 0.038
  32. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.